These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30394548)

  • 21. Analysis of Screening Electrocardiogram for the Subcutaneous Defibrillator in Adults with Congenital Heart Disease.
    Thomas VC; Peterson M; McDaniel M; Restrepo H; Rothman A; Jain A
    Pediatr Cardiol; 2017 Aug; 38(6):1162-1168. PubMed ID: 28534239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcutaneous implantable cardioverter defibrillator: Can it overtake its transvenous counterpart.
    Savarimuthu S; Roy S; Obeidat M; Harky A
    Pacing Clin Electrophysiol; 2021 Aug; 44(8):1413-1420. PubMed ID: 33878197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eligibility of cardiac resynchronization therapy patients for subcutaneous implantable cardioverter defibrillators.
    Moubarak G; Maison-Blanche P; Thomas O
    J Electrocardiol; 2018; 51(3):531-533. PubMed ID: 29273233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Which patients are not suitable for a subcutaneous ICD: incidence and predictors of failed QRS-T-wave morphology screening.
    Olde Nordkamp LRA; Warnaars JLF; Kooiman KM; de Groot JR; Rosenmöller BRAM; Wilde AAM; Knops RE
    J Cardiovasc Electrophysiol; 2014 May; 25(5):494-499. PubMed ID: 24320684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acceptance and psychological impact of implantable defibrillators amongst adults with congenital heart disease.
    Bedair R; Babu-Narayan SV; Dimopoulos K; Quyam S; Doyle AM; Swan L; Gatzoulis MA; Wong T
    Int J Cardiol; 2015 Feb; 181():218-24. PubMed ID: 25528316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of a novel automatic screening tool for determining eligibility for a subcutaneous implantable cardioverter-defibrillator.
    Sakhi R; Yap SC; Michels M; Schinkel AFL; Kauling RM; Roos-Hesselink JW; Theuns DAMJ
    Int J Cardiol; 2018 Dec; 272():97-101. PubMed ID: 30005832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Right Parasternal Lead Placement Increases Eligibility for Subcutaneous Implantable Cardioverter Defibrillator Therapy in Adults With Congenital Heart Disease.
    Okamura H; McLeod CJ; DeSimone CV; Webster TL; Bonnichsen CR; Grogan M; Phillips SD; Connolly HM; Ammash NM; Warnes CA; Friedman PA
    Circ J; 2016 May; 80(6):1328-35. PubMed ID: 27109124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conventional and right-sided screening for subcutaneous ICD in a population with congenital heart disease at high risk of sudden cardiac death.
    Alonso P; Osca J; Rueda J; Cano O; Pimenta P; Andres A; Sancho MJ; Martinez L
    Ann Noninvasive Electrocardiol; 2017 Nov; 22(6):. PubMed ID: 28508439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Left and Right Parasternal Sensing for the S-ICD in Adult Congenital Heart Disease Patients and Normal Controls.
    Wilson DG; Zeb M; Veldtman G; Dimitrov BD; Morgan JM
    Pacing Clin Electrophysiol; 2016 Mar; 39(3):282-90. PubMed ID: 26694691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-center experience with implantable cardioverter-defibrillators in adults with complex congenital heart disease.
    Khanna AD; Warnes CA; Phillips SD; Lin G; Brady PA
    Am J Cardiol; 2011 Sep; 108(5):729-34. PubMed ID: 21684513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High rate of subcutaneous implantable cardioverter-defibrillator sensing screening failure in patients with Brugada syndrome: a comparison with other inherited primary arrhythmia syndromes.
    Conte G; Kawabata M; de Asmundis C; Taravelli E; Petracca F; Ruggiero D; Caputo ML; Regoli F; Chierchia GB; Chiodini A; Del Bufalo A; Moccetti T; Goya M; Hirao K; Vicentini A; De Ferrari GM; Brugada P; Auricchio A
    Europace; 2018 Jul; 20(7):1188-1193. PubMed ID: 28340026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subcutaneous implantable cardioverter defibrillator eligibility according to a novel automated screening tool and agreement with the standard manual electrocardiographic morphology tool.
    Francia P; Ziacchi M; De Filippo P; Viani S; D'Onofrio A; Russo V; Adduci C; Biffi M; Ferrari P; Bianchi V; Ammendola E; Palano F; Frisoni J; Valsecchi S; Lovecchio M; Bongiorni MG
    J Interv Card Electrophysiol; 2018 Jun; 52(1):61-67. PubMed ID: 29502193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eligibility for subcutaneous implantable cardioverter-defibrillator in patients with left ventricular assist device.
    Zormpas C; Eiringhaus J; Hillmann HAK; Hohmann S; Müller-Leisse J; Schmitto JD; Veltmann C; Duncker D
    J Interv Card Electrophysiol; 2021 Mar; 60(2):303-311. PubMed ID: 32613315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brugada syndrome: Eligibility for subcutaneous implantable cardioverter-defibrillator after exercise stress test.
    von Hafe P; Faria B; Dias G; Cardoso F; Alves MJ; Alves A; Rodrigues B; Ribeiro S; Sanfins V; Lourenço A
    Rev Port Cardiol (Engl Ed); 2021 Jan; 40(1):33-38. PubMed ID: 33436324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exercise stress test reveals ineligibility for subcutaneous implantable cardioverter defibrillator in patients with Brugada syndrome.
    Tachibana M; Nishii N; Morita H; Nakagawa K; Watanabe A; Nakamura K; Ito H
    J Cardiovasc Electrophysiol; 2017 Dec; 28(12):1454-1459. PubMed ID: 28800177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Electrocardiographic Markers of Appropriate Implantable Cardioverter-Defibrillator Therapy in Young People with Congenital Heart Diseases.
    Benítez Ramos DB; Cabrera Ortega M; Castro Hevia J; Dorantes Sánchez M; Alemán Fernández AA; Castañeda Chirino O; Cruz Cardentey M; Martínez López F; Falcón Rodríguez R
    Pediatr Cardiol; 2017 Dec; 38(8):1663-1671. PubMed ID: 28871362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implantable cardioverter defibrillator therapy in adults with congenital heart disease: who is at risk of shocks?
    Koyak Z; de Groot JR; Van Gelder IC; Bouma BJ; van Dessel PF; Budts W; van Erven L; van Dijk AP; Wilde AA; Pieper PG; Sieswerda GT; Mulder BJ
    Circ Arrhythm Electrophysiol; 2012 Feb; 5(1):101-10. PubMed ID: 22095638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of diurnal variations in the QRS complex and T waves on the eligibility for subcutaneous implantable cardioverter-defibrillators.
    Miwa N; Nagata Y; Yamaguchi T; Nagase M; Sasaki T; Nozato T; Ashikaga T; Goya M; Hirao K
    Heart Rhythm; 2019 Jun; 16(6):913-920. PubMed ID: 30616021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The utility of routine clinical 12-lead ECG in assessing eligibility for subcutaneous implantable cardioverter defibrillator.
    Thomas JA; Perez-Alday EA; Hamilton C; Kabir MM; Park EA; Tereshchenko LG
    Comput Biol Med; 2018 Nov; 102():242-250. PubMed ID: 29754992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eligibility of Pacemaker Patients for Subcutaneous Implantable Cardioverter Defibrillators.
    Ip JE; Wu MS; Kennel PJ; Thomas G; Liu CF; Cheung JW; Markowitz SM; Lerman BB
    J Cardiovasc Electrophysiol; 2017 May; 28(5):544-548. PubMed ID: 28185354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.